企業プロフィール
Beyond Air 株価・ニュース・カタリスト
- ティッカー:
- XAIR
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
5.71 USD (-9.58%)
終値
最終更新: 2026年8月17日
5.97M USD
時価総額
株価変動の要因
As of Aug 17, 2026, XAIR closed down 9.58% at $5.71. No new same-company headline was identified in the current news window.
企業概要
Nitric Oxide Medical Technology Platform
Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors. Its first product, LungFit PH, is FDA-approved and CE-marked for hypoxic respiratory failure in term and near-term newborns.
Cylinder-Free LungFit System
LungFit is a phasic-flow nitric oxide generation and delivery system that produces nitric oxide from ambient air without high-pressure cylinders. The design reduces cylinder inventory, storage requirements, and nitrogen dioxide venting while simplifying hospital operations.
Commercial and International Reach
Beyond Air is commercializing LungFit PH in the United States and through a distribution network covering more than 45 countries. Regional partners provide regulatory and market access beyond the company’s direct U.S. organization.
Second-Generation Product Strategy
The second-generation LungFit PH is designed to be smaller, lighter, easier to operate, and suitable for a broader range of care settings. The updated system is also intended to support patient transport use.
Nitric Oxide Platform Beyond Respiratory Care
Beyond Air is also exploring nitric oxide biology in neurological disease and solid tumors. These programs extend the company’s technology base beyond hospital respiratory delivery, although LungFit PH remains its commercial foundation.
今後のカタリスト
- An FDA decision is pending on the PMA supplement for the second-generation LungFit PH system.
- The PMA supplement also seeks an expanded label covering use during air and ground patient transport.
- Regional regulatory submissions for LungFit PH continue through local partners, with future approvals determining the scope of international commercialization.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。